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Abstract
Aims Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection
fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy-related cardiac dysfunction (CTRCD).
Our aim was to analyse the potential benefit of sacubitril/valsartan in patients with CTRCD.
Methods and results We performed a retrospective multicentre registry (HF-COH) in six Spanish hospitals with cardio-
oncology clinics including all patients treated with sacubitril/valsartan. Demographic and clinical characteristics and laboratory
and echocardiographic data were collected. Median follow-up was 4.6 [1; 11] months. Sixty-seven patients were included (me-
dian age was 63 ± 14 years; 64% were female, 87% had at least one cardiovascular risk factor). Median time from anti-cancer
therapy to CTRD was 41 [10; 141] months. Breast cancer (45%) and lymphoma (39%) were the most frequent neoplasm, 31%
had metastatic disease, and all patients were treated with combination antitumor therapy (70% with anthracyclines). Thirty-
nine per cent of patients had received thoracic radiotherapy. Baseline median LVEF was 33 [27; 37], and 21% had atrial fibril-
lation. Eighty-five per cent were on beta-blocker therapy and 76% on mineralocorticoid receptor antagonists; 90% of the
patients were symptomatic NYHA functional class ≥II. Maximal sacubitril/valsartan titration dose was achieved in 8% of pa-
tients (50 mg b.i.d.: 60%; 100 mg b.i.d.: 32%). Sacubitril/valsartan was discontinued in four patients (6%). Baseline N-
terminal pro-B-type natriuretic peptide levels (1552 pg/mL [692; 3624] vs. 776 [339; 1458]), functional class (2.2 ± 0.6 vs.
1.6 ± 0.6), and LVEF (33% [27; 37] vs. 42 [35; 50]) improved at the end of follow-up (all P values ≤0.01). No significant statistical
differences were found in creatinine (0.9 mg/dL [0.7; 1.1] vs. 0.9 [0.7; 1.1]; P = 0.055) or potassium serum levels (4.5 mg/dL
[4.1; 4.8] vs. 4.5 [4.2; 4.8]; P = 0.5). Clinical, echocardiographic, and biochemical improvements were found regardless of the
achieved sacubitril–valsartan dose (low or medium/high doses).
Conclusions Our experience suggests that sacubitril/valsartan is well tolerated and improves echocardiographic functional
and structural parameters, N-terminal pro-B-type natriuretic peptide levels, and symptomatic status in patients with CTRCD.
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Background
Cancer therapy-related cardiac dysfunction (CTRCD) is a com-
plication of growing interest because of its potentially serious
impact on patient outcome. CTRCD has been associated with
a particularly poor prognosis compared with other forms of
cardiomyopathy1,2; however, when standard medical treat-
ment derived from clinical practice guidelines for heart failure
is systematically applied, a much better prognosis is obtained,
with a mortality risk similar to that of non-ischaemic dilated
cardiomyopathy.3
Current guidelines and recent expert consensus of heart
failure of the European Society of Cardiology4,5 recommend
sacubitril–valsartan for patients with heart failure and re-
duced left ventricular ejection fraction (HFrEF) for further re-
duction of mortality and hospitalizations,6 but there is lack of
evidence of its performance under real-word conditions (ef-
fectiveness) in patients with cancer and HFrEF. Indeed, pa-
tients with a history of chemotherapy-related HFrEF less
than 12 months prior were an exclusion criterion for
PARADIGM-HF trial.6
Objective
The aim of this study was to analyse the effectiveness of
sacubitril–valsartan in onco-haematological patients with
CTRCD followed by cardio-oncology units in Spain.
Methods
We performed a retrospective multicentre registry in six
Spanish hospitals with cardio-oncology units including all can-
cer patients treated with sacubitril–valsartan symptomatic
HFrEF [left ventricular ejection fraction (LVEF) < 40%] due
to cancer therapies.7 The study complied with the Declaration
of Helsinki and was approved by the Ethics Committee of
Clinical Investigation, University Hospital of Salamanca,
Spain. Demographic and clinical characteristics including type
of neoplasms and cancer treatment were obtained. Physical
examination (blood pressure and heart rate) and blood sam-
ples laboratory data, including N-terminal pro-B-type natri-
uretic peptide (NT-proBNP), potassium levels, and renal
function, were collected. A transthoracic echocardiography
for each participant was performed before starting
sacubitril–valsartan and a median of 4.6 [1; 11] months after
sacubitril–valsartan treatment.
Data are presented as mean ± standard deviation for nor-
mal quantitative variables and as median [inter-quartile
range] for non-normal ones. For categorical variables, data
are expressed as frequencies and percentages. Paired sample
t-test and Wilcoxon signed-rank test were used for
comparison. Statistical analyses were performed with SPSS,
Version 23.
Results
Sixty-seven patients were included with a median age of 63 ±
14 years; 64% were female, 87% had at least one cardiovas-
cular risk factor (54% dyslipidaemia, 43% hypertension, and
28% diabetes), and 90% were New York Heart Association
(NYHA) functional class ≥II (61% NYHA II, 28% III, and 1% IV).
The two most common malignancies were breast cancer
(45%) and lymphoma (39%); one-third of patients were un-
dergoing active antineoplastic treatment, and 31% had meta-
static disease. All patients were treated with combination
anti-tumour therapy with a large variety of different antineo-
plastic agents: 70% received anthracyclines, 60% alkylating
agents, 50% antimicrotubule agents, 25% antimetabolites,
22% tyrosine kinase inhibitors, 12% anti-HER2 humanized an-
tibody, 6% topoisomerase inhibitors, and 3% PD-1 inhibitors.
Moreover, 39% of patients had received thoracic
radiotherapy.
Median time from anti-cancer therapy to HFrEF was 43
[10; 141] months. Median time from HFrEF to
sacubitril–valsartan initiation was 13 [2; 52] months.
Sacubitril–valsartan was started in 80% of patients already
treated with angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers, 85% were on beta-blocker
therapy, and 76% on mineralocorticoid receptor antagonists
(Table 1).
The lowest sacubitril–valsartan dose of 50 mg twice daily
(b.i.d.) was initially prescribed in 78% of the patients, and
maximal titration dose (200 mg b.i.d.) was achieved in 8%
of the patients during follow-up (60% 50 mg b.i.d. and 32%
100 mg b.i.d.). Four patients (6%) had to discontinue
sacubitril–valsartan because of adverse events (two patients
due to symptomatic hypotension, one renal function impair-
ment, and one severe pruritus).
Main results data are presented in Figure 1 and Table 2. At
the end of follow-up, reverse remodelling benefits by
sacubitril-valsartan were observed: LVEF significantly im-
proved, and both left ventricular volumes were significantly
reduced compared with basal echocardiography. It is note-
worthy that eight of the patients even normalized (LVEF >
53%). Furthermore, a significant reduction in NT-proBNP
levels was evident. Fifty-six per cent of patients exhibited
an improvement in the exercise tolerance at follow-up, as in-
dicated by the change in NYHA functional class (at the end of
follow-up: 45% of patients with NYHA I and 47% NYHA II).
These clinical, echocardiographic, and biochemical improve-
ments were found regardless of the achieved sacubitril–
valsartan dose (low or medium/high doses) (Table 3).
764 A. Martín-Garcia et al.
DOI: 10.1002/ehf2.12627
ESC Heart Failure 2020; : 763–7677
The glomerular filtrate rate decreased significantly; how-
ever, excluding the patient who discontinued sacubitril-
valsartan because of acute renal failure (Stage 2 of Acute Kid-
ney Injury Network classification: serum creatinine increased
250% over basal), no patient reduced estimated glomerular
filtration rate at follow-up by more than 50% from baseline.
In addition, there were no significant changes in serum creat-
inine or potassium levels.
Discussion
To the best of our knowledge, this is the first multicentre
study to report strong beneficial effect of sacubitril-valsartan
on reverse remodelling, LVEF, and NT-proBNP levels in pa-
tients with CTRCD. In addition, to date, no other multicentre
studies had been published assessing the safety of
sacubitril/valsartan in this special population.
The rapid development of effective oncologic therapies has
improved cancer-free and overall survivals, yet they can
cause CTRCD with a known impact on cancer patient morbid-
ity and mortality. Recently, Fornaro et al.3 reported that pa-
tients with CTRCD treated with optimized heart failure
therapy have comparable overall survival rates with non-
ischaemic dilated cardiomyopathy at 5 (86% and 88%, respec-
tively) and 10 years (61% and 75%, respectively), despite
cancer-related morbidity and mortality.
However, presently, patients with cancer and cardiovascu-
lar disease do not always receive an optimal cardiovascular
treatment; only half of them are treated with guideline-based
therapy or are referred to a cardiology consultation at the
time of cancer diagnosis.8 Prioritization of cardio-oncology
teams is critical to ensure that patients receive the best can-
cer and cardiovascular therapy to improve their overall
prognosis.9
Moreover, we showed a strong beneficial effect of
sacubitril-valsartan on reverse remodelling and LVEF. This
finding is particularly noteworthy because it was obtained,





Angiotensin-converting enzyme inhibitors (ACEis) or
angiotensin receptor blockers (ARBs)
53 (80%) 0%
Beta-blocker therapy 57 (85%) 55 (86%)
Mineralocorticoid receptor antagonists 51 (76%) 43 (67%)
Diuretics 35 (52%) 35 (52%)
Figure 1 Left ventricular ejection fraction before and after sacubitril-
valsartan treatment
Table 2 Remodelling echocardiographic, clinical, and biochemical patient parameters before and after sacubitril–valsartan treatment
Before sacubitril–valsartan After sacubitril–valsartan P value
Left ventricle end-diastolic volume (mL) 144 [119; 184] 129 [107; 168] 0.006
Left ventricle end-systolic volume (mL) 93 [72; 128] 73 [54; 104] <0.001
e/e´ 13 [9; 18] 11 [8; 15] 0.053
Global longitudinal strain (%) 10.5 [13; 7.3] 12 [15; 8] 0.49
Systolic blood pressure (mmHg) 116 [106; 119] 112 [100; 126] 0.006
Diastolic blood pressure (mmHg) 70 [61; 76] 68 [60; 72] 0.30
Heart rate (b.p.m.) 74 [65; 81] 68 [60; 75] 0.01
Creatinine (mg/dL) 0.9 [0.7; 1.1] 0.9 [0.7; 1.1] 0.055
Estimated glomerular filtration rate (mL/min/1.73 m2) 76 [64; 90] 70 [53; 88] 0.02
Potassium serum levels (mg/dL) 4.5 [4.1; 4.8] 4.5 [4.2; 4.8] 0.50
NT-proBNP (pg/mL) 1552 [692; 3624] 776 [339; 1458] 0.001
NYHA functional class 2.2 ± 0.6 1.6 ± 0.6 <0.001
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
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although most of patients were not able to reach the full
dose of the drug. Thus, after our initial observations, one
could speculate that sacubitril significantly improve the man-
agement of CTRCD being necessary in all patients without
specific contraindications.
On the other hand, tolerability of sacubitril-valsartan in our
population was good, and only four patients (6%) had to
withdraw sacubitril–valsartan because of an adverse event.
This percentage was lower than that observed in the PARA-
DIGM population.6
Conclusions
Ours is the most comprehensive study reported so far pre-
senting imaging, clinical, and laboratory data from field prac-
tice experience concerning to patients with CTRCD, before
and after sacubitril–valsartan treatment. We evidenced im-
provements in echocardiographic functional and structural
parameters, NT-proBNP levels, and symptomatic status in this
special oncologic population. Sacubitril–valsartan was also
quite well tolerated in these patients. While more prospec-
tive data are required to confirm the beneficial role of
sacubitril–valsartan in CTRD patients, our findings are promis-
ing and anticipate that sacubitril–valsartan may help to opti-
mize CTRCD management, as in other HFrEF scenarios,
according to current guidelines.4,5
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